Glenmark transfers nebulizer brands to subsidiary for ₹223 Cr
Published on: May 30, 2026, 2:59 a.m. | Source: scanx.trade
Glenmark Pharmaceuticals Limited approved transferring its Nebulizer brands/IP portfolio to subsidiary Glenmark Healthcare Limited for ₹223 Cr. The transaction, expected to close by June 30, 2026, aims to scale the growing respiratory business. The Nebulizer unit reported revenue of ₹71.6 Cr for the nine months ended December 31, 2025.
